On methotrexate treatment of psoriasis. Model of a cytostatics treatment.
D000367:Age Factors; D000505:Alopecia / Q000139:chemically induced; D001284:Atrophy / Q000139:chemically induced; D002280:Basal Cell Carcinoma / Q000139:chemically induced; D003967:Diarrhea / Q000139:chemically induced; D005756:Gastritis / Q000139:chemically induced; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced; D005882:Gingival Diseases / Q000139:chemically induced; D005892:Gingivitis, Necrotizing Ulcerative / Q000139:chemically induced; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000139:chemically induced*; D007165:Immunosuppression Therapy / Q000009:adverse effects*; D007239:Infections / Q000209:etiology; D007249:Inflammation / Q000188:drug therapy; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use*; D009325:Nausea / Q000139:chemically induced; D011565:Psoriasis / Q000188:drug therapy*; D012878:Skin Neoplasms / Q000139:chemically induced; D013281:Stomatitis, Aphthous / Q000139:chemically induced
D008727:Methotrexate